Eribulin in non-small cell lung cancer: challenges and potential strategies
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Eribulin in non-small cell lung cancer: challenges and potential strategies
Authors
Keywords
-
Journal
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 26, Issue 4, Pages 495-508
Publisher
Informa UK Limited
Online
2017-02-06
DOI
10.1080/13543784.2017.1292250
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- 173PTLE3 IS A USEFUL MARKER FOR PREDICTING THE THERAPEUTIC EFFECT OF ERIBULIN CHEMOTHERAPY FOR TRIPLE-NEGATIVE BREAST CANCER
- (2017) S. Kashiwagi et al. ANNALS OF ONCOLOGY
- Phase IB study of eribulin mesylate in combination with carboplatin in patients with advanced solid tumors.
- (2017) U. Swami et al. JOURNAL OF CLINICAL ONCOLOGY
- In vivo imaging of eribulin-induced reoxygenation in advanced breast cancer patients: a comparison to bevacizumab
- (2016) Shigeto Ueda et al. BRITISH JOURNAL OF CANCER
- Cancer statistics, 2016
- (2016) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Abstract OT1-03-19: Design of a phase 1b/2 study to evaluate the efficacy and safety of eribulin mesylate in combination with pembrolizumab in patients with metastatic triple-negative breast cancer
- (2016) E Berrak et al. CANCER RESEARCH
- Termination of Protofilament Elongation by Eribulin Induces Lattice Defects that Promote Microtubule Catastrophes
- (2016) Harinath Doodhi et al. CURRENT BIOLOGY
- New and emerging targeted treatments in advanced non-small-cell lung cancer
- (2016) Fred R Hirsch et al. LANCET
- Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial
- (2016) Patrick Schöffski et al. LANCET
- Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
- (2016) Louis Fehrenbacher et al. LANCET
- Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study
- (2016) Scott Antonia et al. LANCET ONCOLOGY
- Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study
- (2016) Corey J Langer et al. LANCET ONCOLOGY
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy
- (2016) Dickran Kazandjian et al. ONCOLOGIST
- Characterization of a New Small Bowel Adenocarcinoma Cell Line and Screening of Anti-Cancer Drug against Small Bowel Adenocarcinoma
- (2015) Hirobumi Suzuki et al. AMERICAN JOURNAL OF PATHOLOGY
- Effects of Eribulin on Microtubule Binding and Dynamic Instability Are Strengthened in the Absence of the βIII Tubulin Isotype
- (2015) Leslie Wilson et al. BIOCHEMISTRY
- Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an open-label randomized phase 3 trial
- (2015) Javier Cortes et al. BREAST CANCER RESEARCH AND TREATMENT
- A phase I combination dose-escalation study of eribulin mesylate and gemcitabine in patients with advanced solid tumours: a study of the Princess Margaret Consortium
- (2015) S Lheureux et al. BRITISH JOURNAL OF CANCER
- A phase I dose-escalation study of eribulin and S-1 for metastatic breast cancer
- (2015) T Sakiyama et al. BRITISH JOURNAL OF CANCER
- Pharmacodynamics (PD) and pharmacokinetics (PK) of E7389 (eribulin, halichondrin B analog) during a phase I trial in patients with advanced solid tumors: a California Cancer Consortium trial
- (2015) Robert J. Morgan et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Pharmacokinetics of eribulin mesylate in cancer patients with normal and impaired renal function
- (2015) Antoinette R. Tan et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- An Open-Label, Multicenter, Randomized Phase Ib/II Study of Eribulin Mesylate Administered in Combination With Pemetrexed Versus Pemetrexed Alone as Second-Line Therapy in Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Cornelius F. Waller et al. Clinical Lung Cancer
- Phase III Open-Label Randomized Study of Eribulin Mesylate Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane
- (2015) Peter A. Kaufman et al. JOURNAL OF CLINICAL ONCOLOGY
- Eribulin in Cancer Treatment
- (2015) Umang Swami et al. Marine Drugs
- Antitumor and anticancer stem cell activities of eribulin mesylate and antiestrogens in breast cancer cells
- (2015) Junichi Kurebayashi et al. Breast Cancer
- Randomized phase II study of two intercalated combinations of eribulin mesylate and erlotinib in patients with previously treated advanced non-small-cell lung cancer
- (2014) T. S. Mok et al. ANNALS OF ONCOLOGY
- Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies
- (2014) Chris Twelves et al. BREAST CANCER RESEARCH AND TREATMENT
- Phase I study of the halichondrin B analogue eribulin mesylate in combination with cisplatin in advanced solid tumors
- (2014) M Koczywas et al. BRITISH JOURNAL OF CANCER
- Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial–mesenchymal transition (EMT) to mesenchymal–epithelial transition (MET) states
- (2014) T Yoshida et al. BRITISH JOURNAL OF CANCER
- Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models
- (2014) Yasuhiro Funahashi et al. CANCER SCIENCE
- Efficacy and Safety of Eribulin Compared with Treatment of Physician’s Choice (TPC) in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC): Results from a Phase 3 Study
- (2014) D.R. Spigel et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Phase 1 combination study of Eribulin mesylate with trastuzumab for advanced or recurrent human epidermal growth factor receptor 2 positive breast cancer
- (2014) Hirofumi Mukai et al. INVESTIGATIONAL NEW DRUGS
- Gene Expression Profiling Reveals Epithelial Mesenchymal Transition (EMT) Genes Can Selectively Differentiate Eribulin Sensitive Breast Cancer Cells
- (2014) Zoltán Dezső et al. PLoS One
- Eribulin Mesylate Targets Human Telomerase Reverse Transcriptase in Ovarian Cancer Cells
- (2014) Satoko Yamaguchi et al. PLoS One
- Single-cell pharmacokinetic imaging reveals a therapeutic strategy to overcome drug resistance to the microtubule inhibitor eribulin
- (2014) A. M. Laughney et al. Science Translational Medicine
- From micrograms to grams: scale-up synthesis of eribulin mesylate
- (2013) Melvin J. Yu et al. NATURAL PRODUCT REPORTS
- Atom-based enumeration: New eribulin analogues with low susceptibility to P-glycoprotein-mediated drug efflux
- (2012) Melvin J. Yu et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Pharmacokinetics of eribulin mesylate in patients with solid tumours receiving repeated oral rifampicin
- (2012) Lot A. Devriese et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Pharmacokinetics of eribulin mesylate in patients with solid tumors and hepatic impairment
- (2012) L. A. Devriese et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Eribulin mesylate pharmacokinetics in patients with solid tumors receiving repeated oral ketoconazole
- (2012) L. A. Devriese et al. INVESTIGATIONAL NEW DRUGS
- A phase I, open-label, single-arm study for QT assessment of eribulin mesylate in patients with advanced solid tumors
- (2012) Thierry Lesimple et al. INVESTIGATIONAL NEW DRUGS
- Novel second generation analogs of eribulin. Part I: Compounds containing a lipophilic C32 side chain overcome P-glycoprotein susceptibility
- (2011) Sridhar Narayan et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- A Phase II Study of Eribulin Mesylate (E7389) in Patients With Advanced, Previously Treated Non–Small-Cell Lung Cancer
- (2011) Alexander I. Spira et al. Clinical Lung Cancer
- Eribulin—A review of preclinical and clinical studies
- (2011) Umang Swami et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Eribulin mesylate in patients with refractory cancers: a Phase I study
- (2011) Toru Mukohara et al. INVESTIGATIONAL NEW DRUGS
- A Phase II Study of Halichondrin B Analog Eribulin Mesylate (E7389) in Patients with Advanced Non-small Cell Lung Cancer Previously Treated with a Taxane: A California Cancer Consortium Trial
- (2011) Barbara J. Gitlitz et al. Journal of Thoracic Oncology
- Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study
- (2011) Javier Cortes et al. LANCET
- Eribulin Induces Irreversible Mitotic Blockade: Implications of Cell-Based Pharmacodynamics forIn vivoEfficacy under Intermittent Dosing Conditions
- (2010) Murray J. Towle et al. CANCER RESEARCH
- Approval Summary: Pemetrexed Maintenance Therapy of Advanced/Metastatic Nonsquamous, Non-Small Cell Lung Cancer (NSCLC)
- (2010) M. H. Cohen et al. ONCOLOGIST
- Eribulin Binds at Microtubule Ends to a Single Site on Tubulin To Suppress Dynamic Instability
- (2009) Jennifer A. Smith et al. BIOCHEMISTRY
- A Phase I Study of Eribulin Mesylate (E7389), a Mechanistically Novel Inhibitor of Microtubule Dynamics, in Patients with Advanced Solid Malignancies
- (2009) S. Goel et al. CLINICAL CANCER RESEARCH
- Phase I Study of Eribulin Mesylate Administered Once Every 21 Days in Patients with Advanced Solid Tumors
- (2009) A. R. Tan et al. CLINICAL CANCER RESEARCH
- Phase II Study of Eribulin Mesylate, a Halichondrin B Analog, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane
- (2009) Linda T. Vahdat et al. JOURNAL OF CLINICAL ONCOLOGY
- Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship
- (2009) Julian R. Molina et al. MAYO CLINIC PROCEEDINGS
- Delineation of the interactions between the chemotherapeutic agent eribulin mesylate (E7389) and human CYP3A4
- (2008) Z.-Y. Zhang et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search